Follow-up of folinic acid supplementation for patients with cerebral folate deficiency and Kearns-Sayre syndrome by unknown
Quijada-Fraile et al. Orphanet Journal of Rare Diseases  (2014) 9:217 
DOI 10.1186/s13023-014-0217-2RESEARCH Open AccessFollow-up of folinic acid supplementation for
patients with cerebral folate deficiency and
Kearns-Sayre syndrome
Pilar Quijada-Fraile1, Mar O’Callaghan3, Elena Martín-Hernández1, Raquel Montero2,3, Àngels Garcia-Cazorla2,3,
Ana Martínez de Aragón1, Jordi Muchart3, Ignacio Málaga4, Rafael Pardo5, Pedro García-Gonzalez5, Cristina Jou3,
Julio Montoya2,6, Sonia Emperador6, Eduardo Ruiz-Pesini2,6, Joaquín Arenas2,7, Miguel Angel Martin2,7,
Aida Ormazabal2,3, Mercè Pineda2,3, María T García-Silva1,2 and Rafael Artuch2,3*Abstract
Background: Kearns-Sayre syndrome (KSS) is a mitochondrial DNA deletion syndrome that presents with profound
cerebral folate deficiency and other features. Preliminary data support the notion that folinic acid therapy might be
useful in the treatment of KSS patients. Our aim was to assess the clinical and neuroimaging outcomes of KSS
patients receiving folinic acid therapy.
Methods: Patients: We recruited eight patients with diagnoses of KSS. Four cases were treated at 12 de Octubre
Hospital, and the other two cases were treated at Sant Joan de Déu Hospital. Two patients refused to participate in
the treatment protocol.
Methods: Clinical, biochemical and neuroimaging data (magnetic resonance imaging or computed tomography
scan) were collected in baseline conditions and at different time points after the initiation of therapy. Cerebrospinal
fluid 5-methyltetrahydrofolate levels were analysed with HPLC and fluorescence detection. Large-scale mitochondrial
DNA deletions were analysed by Southern blot.
Treatment protocol: The follow-up periods ranged from one to eight years. Cases 1–4 received oral folinic acid at a dose
of 1 mg/kg/day, and cases 6 and 8 received 3 mg/kg/day.
Results: No adverse effects of folinic acid treatment were observed. Cerebral 5-methyltetrahydrofolate deficiencies
were observed in all cases in the baseline conditions. Moreover, all three patients who accepted lumbar puncture after
folinic acid therapy exhibited complete recoveries of their decreased basal cerebrospinal fluid 5-methyltetrahydrofolate
levels to normal values. Two cases neurologically improved after folinic therapy. Disease worsened in the other
patients.
Post-treatment neuroimaging was performed for the 6 cases that received folinic acid therapy. One patient
exhibited improvements in white matter abnormalities. The remaining patients displayed progressions in
subcortical cerebral white matter, the cerebellum and cerebral atrophy.
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Conclusions: Four patients exhibited clinical and radiological progression of the disease following folinic acid
treatment. Only one patient who was treated in an early stage of the disease exhibited both neurological and
radiological improvements following elevated doses of folinic acid, and an additional patient experienced
neurological improvement. Early treatment with high-dose folinic acid therapy seems to be advisable for the
treatment of KSS.
Trial registration: EudracT2007-00-6748-23
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NeuroimagingBackground
Mitochondrial DNA (mtDNA) single-large deletion
syndromes predominantly comprise three phenotypes:
Kearns-Sayre syndrome (KSS: ORPHA480), Pearson syn-
drome (ORPHA699), and different subtypes of progressive
external ophthalmoplegia [1]. Kearns-Sayre syndrome is a
multisystemic disorder caused mainly by single deletions
in mtDNA [2]. The clinical features of these syndromes
have been extensively studied over the last decades. Al-
though mtDNA deletions are present in different tissues
of KSS patients, the central nervous system (CNS) is the
most severely affected system.
The choroid plexus is a target organ of KSS. The chor-
oid plexus is the main site of active folate transport to
the CNS [3]. In addition to this function, the choroid
plexus has other roles in the active transport of essential
micronutrients from the blood into the cerebrospinal
fluid (CSF) and also transports many exogenous chemicals
and waste products from brain metabolism out of the CSF
[4]. Analyses of the CSF of KSS patients have shown
high lactate and protein levels, dramatic reductions in
5-methyltetrahydrofolate (5-MTHF) in most cases, and
other biochemical alterations [5,6]. It has been sug-
gested that the accumulation of mutated mtDNA copies
in the choroid plexus plays an important role in causing
the increases in CSF protein levels and reductions in
5-MTHF levels that are characteristic of KSS [7]. The
association between cerebral folate deficiency and KSS
was first described in 1983 [8,9]. It was recently re-
ported that cerebral folate deficiency is a common fea-
ture of KSS and other mitochondrial disorders [10,11].
Pineda et al. [5], described a positive clinical response
following folinic therapy in a patient with a mtDNA
deletion and cerebral folate deficiency. Preliminary
data support the notion that folinic acid therapy may
be useful for the treatment of KSS patients who
present with cerebral folate deficiency, although no
long-term follow-up studies have been reported. This
statement is supported by the essential role of folate in
brain metabolism because folate participates in hundreds
of methylation reactions, and folate is essential for the
methylation and stability of myelin [5].The objective of this study was to assess the clinical
and neuroimaging outcomes and biochemical data of pa-
tients with Kearns-Sayre syndrome who presented with




Design: open label study. We recruited eight patients
with diagnoses of mtDNA single large-scale deletion
syndrome and cerebral folate deficiency. Case 1 had
Pearson’s syndrome at onset but evolved to a complete
form of KSS. All cases fulfilled the criteria for KSS dur-
ing the time of the study. Data from some of the patients
have been published elsewhere [5,11,12]. The patients
were recruited at the Hospital 12 de Octubre (Madrid),
Hospital San Joan de Déu (Barcelona) and Hospital
Central de Asturias (Oviedo). Cases 1–4 were treated
at 12 de Octubre Hospital, and cases 6 and 8 were
treated at Sant Joan de Déu Hospital. Two cases (5 and 7)
refused to participate in the treatment protocol but were
included in the baseline patient descriptions (see the
tables).
The ages, ages at disease onset, ages at the initiation of
folinic acid supplementation, clinical assessment by the
Newcastle Mitochondrial Disease Ratings Scale, CSF folate
values, clinical features and the results of molecular stud-
ies (% mtDNA deletion and size) and histopathological
studies of muscle biopsies of the patients are provided in
Table 1.
Methods
Clinical, biochemical and neuroimaging data (MRI or
CT scan) were collected in baseline conditions and at
different points after the initiation of therapy (Tables 1, 2
and 3). General and neurological physical examination
was performed during visits that occurred at six-month
intervals. Clinical outcome was assessed using the
Newcastle Paediatric Mitochondrial Disease ratings
Scale (NPDMS) in patients below to 18 years and the
Newcastle Mitochondrial Disease Adult ratings scale
(NMDAS) when patients reached adult age [13,14].
Table 1 Age, age at disease onset, age at the initiation of folinic acid treatment, CSF folate values, clinical features, molecular studies (% deletion and size)
and histopathology on muscle biopsy
Case 1a Case 2a Case 3a Case 4a Case 5 Case 6a Case 7 Case 8a
Age (y) 12 16 23 20 42 14 29 16
Onset age (y) 0.3 10 10 6 9 9 8 7
Age of folinic acid treatment 8.5 11 17 14 - 13 - 8
CSF Folate (nmol/L) 7 5.6 2 6 24 4 1 8
Clinical features and age
NPMDS Scoreb 31 7 26 29 100 (at 33y)** 17 114** 20
Ophthalmoplegia and retinopathy 7 y 10 y 10 y 7 y 18 y 9 y/12 y 10 y 9 y
Cerebellar ataxia 7 y 15 y 7 y 27 y 9 y 8 y 7 y
Myopathy 7 y 10 y 15 y 7 y 12 y 9 y 10 y 8 y
Cardiac conduction block 9 y 11 y 14 y 9 y 30 y 14 y 12 y
Diabetes mellitus 12 y 12 y 15 y
Hearing loss + 12 y 14 y 21 y 11 y 9 y
Others Renal Fanconi 2 y Exocrine
pancreatic insufficiency 3 y
Suprarenal insufficiency 7 y
Pacemaker Myoclonic jerks












75% 18% 40% 71% 77% 80% 62% 73%
6900 7900 7100 5100 2434 5800 4977 4121
Histopathology Muscle biopsy - Normal Lipids in fibers Raged-red fibers
(RRF), COX negative
RRF - RRF RRF partial COX
deficient-fibers















Table 2 Biochemical data and folinic acid therapy in KSS patients

















1 8.5 1 0.8 25 3 7➔48 5.1/- 115/-
2 11 1 3.7 - 1.5 5.6➔60 2.1➔1.4 121➔142
3 17 1 - 20 1.4 2 3.5 165
4 14 1 - - 2.5 6 5.7 169
5 - - - 5.3 2.3 24 5.9 80
6 13 3 - - - 4 4.2 160
7 - - - 9.9 3.5 1 3.5 244
8 8 3 1 1.2 2.5 8➔82 5.2➔1.2 89➔117















Table 3 Neuroimaging (MRI or CT scan) data before and after the initiation of folinic acid therapy and clinical outcome
Cases Time between
images (years)
Atrophy Abnormal high signal on T2-weighted images Clinical outcome NPMDS*
Sections I-III Pre/PostAge at neuroimaging
before therapy
Cerebral Cerebellar Cerebrum subcortical Brain stem Basal ganglia Thalamus Cerebellum
Pre/Post Pre/Post Pre/Post Pre/Post Pre/Post Pre/Post Pre/Post
1 8 0.7 + / ++ +/+ +/+ +/+ 31/40
2 11 2.7 +/ ++ +/+ +/+ 7/14
3 17 3 −/+ + +/+ −/+ + −/+ 26/54**
4* 14 3 −/+ −/+ +/+ −/+ 29/67**
5 + + + + + + Unknown
6 13 2 +/+ +/+ −/+ 17/22
7 + + + + Unknown
8 8 2 +/ - 20/24
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children with inherited mitochondrial diseases to assess
disease severity. Appropriate age-specific versions of
the NPMDS were utilized: 2–11 years; and 12–18
years. Sections I-III which assesses organ-specific func-
tion was completed in each patient at baseline (before
treatment) and during follow-up. Complementary exams
(electroencephalograms, echocardiograms, electrocardio-
grams, visual and acoustic evoked potentials) and renal
and endocrine examinations were performed depending
on the clinical condition of the patients. The follow-up pe-
riods ranged from one to eight years.
Biochemical methods: Plasma lactate and folate con-
centrations were measured with standard automated
procedures. Lumbar punctures were performed to CSF
in all cases according to a previously reported protocol
[15]. CSF lactate and total protein concentrations were
analysed with automated spectrophotometric proce-
dures, and CSF 5-MTHF was determined by HPLC
with fluorescence detection according to previously
reported procedures [15].Genetic analysis
DNA was isolated from the muscle in all cases with the
exception of case 1 in which DNA was isolated from the
blood. The mtDNA large-scale deletions were analysed
by Southern blot.
Brain magnetic resonance imaging (MRIs) were per-
formed in a 1.5 T Philips® or a 1.5 T General Electric®
machine, and the protocol included T1- and T2-weighted
images, diffusion weighted imaging (DWI), MR spec-
troscopy and fluid attenuated inversion recovery (FLAIR).
MRIs were performed in all cases with the exception of
case 4 who did not under MRI because of a pacemaker. A
computed tomography (CT) scan was performed in this
case. We evaluated the images before and at different
times following folinic acid treatment (Table 3).Treatment protocol
Cases 1–4 received oral folinic acid at a dose of 1 mg/kg/
day, and cases 6 and 8 received higher doses (3 mg/kg/
day, Table 2). The doses of folinic acid were selected ac-
cording to previous reported protocols for the treatment
of profound cerebral folate deficiencies [5,16,17]. Lumbar
punctures following therapy were performed in three
patients (cases 1, 2 and 8; Table 2). The remaining cases
declined undergoing lumbar puncture.
Informed consent was obtained from the families of
the patients. The ethics committees of the Sant Joan de
Déu, 12 de Octubre and Central de Asturias Hospitals
approved the study. The clinical trial was funded and
approved by the Instituto de Salud Carlos III, Spanish
Ministry of Health (EC07/90272).Results
No adverse effects were observed during folinic acid
treatment. The clinical outcomes that followed are
provided in Table 3. Two cases neurologically improved
following folinic acid therapy (cases 6 and 8). In case 6,
the NPMDS score worsened from 17 (at baseline) to 22
(2 years after folinic acid supplementation). This outcome
was due to mild alterations in endocrine system (parathy-
roid hormone disturbances secondary to moderate renal
function impairment) and asymptomatic changes in ECG
(section II of NPMDS). Vision at night worsened second-
ary to the instauration of retinopathy. Interestingly, some
neurological items (section III of NPMDS) remained
stable, such as ptosis and eye movements, the mild myop-
athy with symmetrical weakness of hip and shoulder gir-
dle. No neuropathy was developed. Remarkably, cerebellar
ataxia and tremor improved. In case 8, the NPMDS score
worsened from 20 (baseline) to 24 (2 years after folinic acid
supplementation). This outcome was due to progression of
hearing loss to severe deafness, secondary problems with
communication, feeding problems with gastrostomy and
the change of the educational achievement attending in a
special school (section I of NPMDS). Mild constipation,
asymptomatic ECG changes, mild renal function impair-
ment and anemia were observed in this period (section II
of NPMDS). Interestingly, some neurological items (section
III of NPMDS) remained stable: mild myopathy with
symmetrical weakness of hip and shoulder girdle un-
changed and neuropathy remained moderate. A recu-
peration ad-integrum of visual conduction after visual
evoked potentials study was surprisingly found, cere-
bellar ataxia and tremor improved, and the patient re-
covered ambulation. At the time of the initiation of
treatment, this patient presented with an incomplete
KSS syndrome and later fulfilled the criteria for this
disorder (Table 1). The disease states worsened in the
remaining cases. Case 1 died at age 13. Cases 5 and 7
were adults, refused to be treated and were lost during
the follow-up period.
The biochemical data are displayed in Table 2. Severe
cerebral 5-MTHF deficiencies were observed in all cases
in the baseline conditions, with the exception of case 5, who
presented with a moderate deficiency. The plasma folate
levels were within the normal range except for cae 8. The
CSF protein concentrations were greater than 100 mg/dL in
six of the eight patients. Three patients agree to undergo
lumbar puncture following folinic acid therapy (cases 1, 2
and 8), and the low CSF folate levels were reversed in all of
these patients and reached normal values. The CSF protein
concentrations remained elevated after treatment (Table 2).
Regarding the neuroimaging, at the time of the diag-
noses of cerebral folate deficiency, the main features
were abnormal MRIs with elevated signals in the T2-
weighted images and the DWI images in the subcortical
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of eight cases) and thalamus (four out of eight cases).
Cases 5 and 7 exhibited cerebellar and cerebral atrophy,
respectively (Table 3). Neuroimaging following treatment
was performed in the six cases who received folinic acid
therapy. Case 8 exhibited improvement in the white
matter abnormalities (Figure 1). The remaining patients
exhibited progression in the abnormalities of the sub-
cortical cerebral white matter, cerebellum and cerebral
atrophy (Additional files 1, 2, 3, 4 and 5).
Discussion
This is the follow-up of a series of KSS patients who
were treated with folinic acid. This disorder is an ex-
ample of choroid plexus failure in which the transport of
folate from the blood into the CSF is inadequate and
causes profound cerebral folate deficiency in the major-
ity of cases [4,6,7]. Although the pathophysiology of KSS
is complex and includes several aspects other than cere-
bral folate deficiency, the key role of this vitamin in
brain function strongly supports folinic acid supplemen-
tation for these patients.
Clinical follow-up revealed that several neurological
disturbances improved in cases 6 and 8, but the disease
progressed in all patients evaluated by the Newcastle
Scales, although very mildly in cases 6 and 8. One ex-
planation for these findings is that brain is a target organ
for folate deficiency in KSS patients, but probably not
the other peripheral tissues. Moreover, the folinic treat-
ment doses were higher for cases 6 and 8 (3 mg/kg/day).
Although the post-treatment lumbar punctures that
were performed in cases 1 and 2 (who received doses of
1 mg/kg/day) revealed that the 5–MTHF CSF levels
reached normal values following folinic acid therapy,
these values were still lower than that observed in case 8Figure 1 (Case 8): MRI coronal T2W. Abnormal high signal sparing the s
folinic acid treatment were detected (A), improving after 2 years of folinic
in MRI axial T2W was also observed before folinic acid treatment (C). Decre
matter signal (D).(Table 2). It is difficult to exclude other factors poten-
tially associated with the beneficial outcome observed in
this work. Lactate values decreased in the second CSF
sample in the 2 cases studied, but this observation may
be anecdotic since it is not uncommon that lactate values
are normal in mitochondrial disorders. Total protein
values increased after folinic acid treatment, suggesting
that the transport through choroid plexus remained
impaired. Folinic doses from 0.5 to 1.8 mg/kg/day have
previously been applied in certain non-mitochondrial
diseases that present with cerebral folate deficiency
and resulted in improvements in some neurological
signs [16,17]. However, the underlying pathophysiological
mechanisms of these clinical conditions might be different
from those of KSS; consequently, the required folinic
doses are presumably different.
Case 8 recovered ambulation and exhibited improve-
ments in the MRI disturbances. This patient began treat-
ment earlier than did the others with the exception of case
1, who began treatment at a similar age (8.5 years) but did
not improve. However, case 1 presented with Pearson syn-
drome; therefore the phenotype of this patient was more
severe than that of case 8. Furthermore, case 8 received
folinic acid before he met the main clinical criteria for
KSS syndrome. This patient was reported in 2006 [5] and
exhibited abnormal subcortical white matter without basal
ganglia or brain stem involvement on MRI at onset, which
indicated that this patient was in the early stage of the dis-
ease. These findings suggest that this patient might have
improved due to both the early treatment and the high
dose of folinic acid. This finding indicates the importance
of performing early lumbar punctures to detect cerebral
folate deficiencies and initiate therapy as early as pos-
sible. Clinical improvements have been anecdotally re-
ported in cases exhibiting cerebral folate deficienciesubcortical white matter with slightly periventricular location before
acid treatment (B). Abnormal high signal in the parietal white matter
ased of high signal after 2 years of treatment with near normal white
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with mitochondrial respiratory chain complex I deficiency
and cerebral 5-MTHF deficiency was treated with a folinic
dose of 1.2 mg/kg/day. Hypotonia and ataxia improved in
this patient, and the abnormal myelination patterns ob-
served on neuroimaging were reversed following treat-
ment for more than three years [18]. However, this patient
exhibited a baseline CSF 5-MTHF value of 38.5 nmol/L,
which is significantly higher than those observed in KSS.
The neuroimaging features observed in our cases are
in accordance with those reported in other publications.
Patients with KSS classically exhibit cerebral and cere-
bellar atrophy and high-signal lesions in the subcortical
white matter on T2-weighted images [19] with or without
symmetrical involvement of one or more areas that in-
clude the brain stem, globus pallidus, thalamus and cere-
bellum [20]. White matter involvement is predominantly
peripheral and includes early involvement of the subcor-
tical U fibres and sparing of the periventricular fibres [21].
The primary involvement of the subcortical white matter
discriminates KSS from other white matter diseases such
as lysosomal and peroxisomal disorders in which the sub-
cortical regions are affected only later in the process [22].
In young adults or children, the combination of bilateral
high-signal lesions in the globus pallidus and high-signal
foci in the subcortical cerebral white matter is characteris-
tic of KSS [23]. The subcortical cerebral white matter is
often abnormal. However, basal ganglia involvement like
that which we observed in our patients has not been
reported in any studies [24]. Cerebellar and/or cerebral
atrophy were present in the older patients (cases 3, 4, 5
and 7), which is in accordance with the results reported
by Chu et al. [20].
MRI abnormalities have been shown to increase in
parallel with the neurologic progression of KSS [25], and
we observed this pattern in patients 1, 2, 3 and 4. MRIs
revealed progression in all of the cases with the excep-
tion of case 8. However, the interval between the ac-
quisitions of the images was different in each case.
Interestingly, all cases had ataxia except case 2. Some
of the patients did not exhibit abnormalities in the
cerebellum on the initial MRI but exhibited such ab-
normalities later. Interestingly, case 6 exhibited im-
provements in ataxia following folinic therapy but
showed progression on MRI. In KSS, the correlations
between cerebellar ataxia and MRI findings can be
weak [20]. Furthermore, the effects of folinic acid ther-
apy on brain are not completely understood, but probably
they are wider than those related with neuroimaging
changes, since brain is a target organ for folate deficiency.
Otherwise, the progression of signal abnormalities coin-
cides with neurologic deterioration. Therefore, follow-up
MRIs might be useful for the assessment of the progres-
sion of this disease [26].MRI signal changes do not necessarily indicate dys-
function. Nevertheless, DWI, which shows restrictions in
diffusion and can detect acute ischemic lesions in stroke
patients, might be capable of indicating acute energy
deprivations. Abnormal DWI results were found in our
patients. The pathophysiology of diffusion abnormalities
that are associated with degenerative disorders such as
mitochondrial diseases remain to be clarified [27]. The
affected regions (particularly the brain stem) are more
sensitive to energy deficiencies than are other brain
areas and have been shown to be affected in patients
with acute energy deprivation syndromes, such as
Wernicke’s encephalopathy and Leigh syndrome. The
pathologic features of the postmortem brains of patients
with KSS include spongiform degenerations, necrosis and
gliosis. Such changes are also present in other diseases
such as Wilson disease and Creutzfeld-Jacob disease.
These findings suggest that mechanisms other than cere-
bral folate deficiency could be involved in the neuroimag-
ing abnormalities observed in KSS.Conclusions
Cerebral 5-MTHF deficiency was observed in all eight
patients with KSS. Neuroimaging revealed lesion that have
been reported to be characteristic of KSS. The majority of
our patients exhibited clinical and radiological progression
of the disease despite the restoration of normal CSF
5-MTHF values due to folinic treatment. Only one
patient who was treated in the early stage of the disease
exhibited neurological and radiological improvement fol-
lowing high-dose folinic acid therapy. Thus, the early initi-
ation of high-dose folinic acid treatment seems advisable
for KSS syndrome, at least to improve the neurological
outcome.Additional files
Additional file 1: Case 1. MRI axial T2W showed abnormal high signal
in cerebellum (A), globus pallidus (B) and subcortical white matter (C).
Additional file 2: Case 2. Multi Vane T2-Weighted TSE (T2W-MV) disclosed
hyperintensity in dorsal brain stem (A), globus pallidus atrophy (B), subcortical
retraction and white matter hyperintensity (C).
Additional file 3: Case 3. DWI showed hyperintensity in brain stem (A),
in left pallidum with restricted difussion (low ADC) (B) and in subcortical
white matter with FLAIR (C).
Additional file 4: Case 4. Computed Tomography scan: White matter
hypondensity in posterior fossa (A), basal ganglia (B) and subcortical
white matter (C) was observed.
Additional file 5: Case 6. MRI axial T2W. Abnormal high signal in
brainstem (A) and globus pallidus (B) was observed. The same lesions are
shown in DWI (C,D).
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